EP3665196
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP
:
EP einkaleyfi: Þýðing ekki lögð inn:
8.8.2018:
19.10.2022:
18755421.7
:
7.8.2038
:
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP
8.8.2018
19.10.2022
:
F. Hoffmann-La Roche AG:
Grenzacherstrasse 124, 4070 Basel, CH
:
NanoString Technologies, Inc.:
530 Fairview Ave North, Seattle, WA 98109, US
:
OESTERGAARD, Mikkel Zahle:
8702 Zollikon, CH
:
201762542489 P:
8.8.2017:
US
:
EP2018071462:
8.8.2018
:
C07K 16/28, A61K 39/395